Clinical Trials Directory

Trials / Completed

CompletedNCT02874560

Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia

Status
Completed
Phase
Study type
Observational
Enrollment
364 (actual)
Sponsor
Janssen-Cilag Ltd. · Industry
Sex
All
Age
18 Years – 37 Years
Healthy volunteers
Not accepted

Summary

In a population of patients suffering from schizophrenia being treated for an episode of clinical destabilization and followed for a period of twelve months, the main objective is to evaluate the proportion of patients achieving functional remission and its relationship to clinical remission.

Detailed description

Prospective, national, noninterventional study. One year follow up with three evaluation dates (D0, D180 and D360). The participation of a subject in this study will in no way impact the regular care of the subject or any benefits they are otherwise entitled to. All treatment decisions will be made at the discretion of the participating physician, in accordance with his clinical practice and with approved local prescribing information. Only data available from clinical practice will be collected. Evaluation methods: patient history and clinical examination, clinical global impression (CGI): Improvement in CGI, social performance evaluation \[functional remission of general schizophrenia (FROGS scale)\], clinical remission evaluation: 8 items of the Positive and negative syndrome (PANSS) Scale, psychosocial remission evaluation (PSP scale), current insight evaluation: insight scale for psychosis, subjective well being under neuroleptic treatment (SWN scale), health condition \[Euro quality of life - 5 Dimensions (EQ-5D)\]; Judgment Criteria: functional remission is defined as an overall score of greater than or equal to (\>=) 57 on the FROGS scale, functional response is defined as improvement of \>= 7 points on the FROGS scale. Safety evaluation: no tolerance analysis will be performed, adverse event (AE) and serious adverse event (SAE) with J\&J products will be collected and transmitted according to J\&J timelines/process.

Conditions

Timeline

Start date
2014-08-12
Primary completion
2017-06-30
Completion
2017-07-12
First posted
2016-08-22
Last updated
2018-10-22

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02874560. Inclusion in this directory is not an endorsement.